CXCL1 and cancer: Studies revealed that chemotherapeutic drug exposure triggers ECs to secrete TNF-α and promotes CXCL1/2 expression in cancer cells, contributing to amplification of CXCL1/2-S100A8/9 loop and inducing the acquisition of therapeutic resistance [29].